The ASCA Program allows medical device manufacturers to use Summary Test Reports from accredited laboratories to demonstrate conformity with FDA-recognized consensus standards. It enhances confidence in testing quality and streamlines premarket review.
The FDA and NAMSA will discuss the Accreditation Scheme for Conformity Assessment (ASCA) Program which enables manufacturers of FDA regulated medical devices to leverage ASCA Summary Test Reports from ASCA-accredited testing laboratories in demonstrating conformity with FDA-recognized consensus standards. The Program enhances confidence in qualified testing laboratories, mitigates risk, and streamlines premarket review of test reports.
Program offerings will:
The ASCA Team is available to present:
• Virtually or in-person
• Domestically and internationally (subject to location, lead time, and presenter availability)
• As independent presenters or as contribution speakers at larger events/meetings
Email [email protected] to learn more!
Eli Lilly and Co.
893 South Delaware Street
Indianapolis, IN 46225
RAPS reserves the right to cancel this program at its sole discretion. RAPS will not be responsible for travel or other costs incurred due to cancellation. All cancellation requests must be submitted in writing to [email protected]. Cancellations will receive a full refund minus a 20% administrative fee. RAPS is unable to accept cancellations by phone.
Paid registration substitutions may be accepted with written approval from RAPS for requests received before the start of the event. To transfer a registration, email [email protected] with the event title, name of the original registrant and the contact information for the new attendee.
A certificate of attendance can be downloaded from the RAPS Learning Portal following the event.
Contact the RAPS Support Center:
Call +1 301 770 2920, ext. 200 (8:30 am–5:30 pm EST, Monday–Friday) or email [email protected].


Senior Policy Advisor , Division of Standards and Conformity Assessment (DSCA) at the Food and Drug Administration

Senior Global Product Marketing Manager of Lab Services and Biological Safety, NAMSA



Senior Policy Advisor , Division of Standards and Conformity Assessment (DSCA) at the Food and Drug Administration
Simon Choi is a Senior Policy Advisor with the Division of Standards and Conformity Assessment (DSCA) at the Food and Drug Administration. He has led major public health projects and initiatives at FDA for medical imaging, directed CT medical imaging safety investigations and developed regulatory policies for Digital Health. Previously, Dr. Choi was Director of the Master of Public Health program at the University of Kansas Medical Center and served as Assistant Professor in the Department of Preventive Medicine.

Senior Global Product Marketing Manager of Lab Services and Biological Safety, NAMSA
Sheri joined NAMSA in 2003 and currently serves as Senior Global Product Marketing Manager of Lab Services and Biological Safety. Sheri has supported customers in a variety of commercial operations and management roles, and was an integral leader in the development of NAMSA’s Biological Safety Consulting business. Additionally, she created the much sought-after NAMSA Training Series (NTS) for the biological evaluation of medical devices. Prior to NAMSA, Sheri was the marketing lead for a mechanical fatigue laboratory and consulting business where she worked primarily with cardiovascular implant manufacturers. Sheri holds a Bachelor’s Degree from the University of Nebraska.
Senior Manager of Laboratory Services, NAMSA
Austin has been with NAMSA for over 21 years in various roles within Biocompatibility. Austin currently acts as the Senior Manager of Laboratory Services, which includes oversight of the sample preparation and in vitro Biocompatibility laboratories In Northwood, OH. He has previous experience in other leadership roles within Biocompatibility and has also served as a GLP Study Director for Biocompatibility testing. Austin is also an active member in a number of AAMI Biological Evaluation Working Groups related to Biocompatibility testing across the ISO 10993 series of standards, with his primary focus being in vitro methods and sample preparation. Additionally, he serves as a U.S. Expert for Sample Preparation, Irritation, and Sensitization through ISO/TC 194. Austin holds a Bachelor’s degree in Pharmaceutical Sciences from the Ohio State University and a MBA from Bowling Green Strate University.